VI.2. Elements for a Public Summary

VI.2.1. Overview of disease epidemiology

Patients may need parenteral nutrition (PN) for any variety of diseases or conditions that impair food intake, nutrient digestion or absorption. Nutriflex Omega special without electrolytes is used to supply energy, essential fatty acids, amino acids, electrolytes and fluids for parenteral nutrition of patients. People of all ages receive parenteral nutrition. People can live well on parenteral nutrition for as long as it is needed.

Many hospitalised patients receive parenteral nutrition. In the U.S. for example, patients received PN in almost 360,000 hospital stays in 2009. About 33% of those were for children and newborns. Individuals can also receive this therapy at home and in long-term care facilities.

VI.2.2. Summary of treatment benefits

The standardised parenteral nutrition containing almost all compounds is suitable for most of the parenteral fed patients. The constituents of Nutriflex Omega special without electrolytes, are generally established for medicinal use, and are acknowledged as being both efficient and safe. The combination chosen in Nutriflex Omega special without electrolytes has positive effects on the body homeostasis.

The important objective of parenteral nutrition is to meet energy requirements and to maintain vital organ structure and function. Protein degradation (catabolism) should be decreased and protein synthesis promoted. Thus amino acid solutions are an essential part of a complete parenteral nutrition regimen providing building blocks for protein synthesis and maintaining nitrogen balance (homeostasis). The amount of nitrogen administered during parenteral nutrition is crucial to reduce catabolism. The infusion of lipid emulsions allows a high energy supply and is indispensable for the supply of essential fatty acids, components of each cell membrane and tissue. In addition, it balances the energy provision by glucose, thereby reducing an overdose of each other. Glucose is the most important energy source for all organs and tissues, and is used exclusively in the brain and nervous tissue, erythrocytes and renal medulla. Additionally, glucose is required for normal metabolism of fatty acids.

VI.2.3. Unknowns relating to treatment benefits

There are no unknown related to treatment benefits for Nutriflex Omega special without electrolytes.

VI.2.4. Summary of safety concerns

Important identi	fied risks	_	
Risk	What is known		Preventability
Allergic reactions (Hypersensitivity)	Most allergic reactions are minor, such as rash. But in some cases, an allergic reaction can be life-threatening and can present with dyspnoea, hypotension and shock. Hypersensitivity reactions to the lipid emulsion of parenteral nutrition have been reported by patients with soybean, peanut or egg allergies as skin eruption and urticaria. They are	•	Nutriflex Omega special without electrolytes must not be used in patients with known allergy to soy bean, egg, peanut or fish protein. Previous allergic reactions to soybean, egg, peanut or fish or to any other substance should be reported to the physician before the beginning of the treatment.

Important identi	fied risks	
Risk	What is known	Preventability
	considered to be fairly	
	rare.	
Intolerance in patients with	There are some rare, genetic disorders of	Nutriflex Omega special
inborn errors of amino acid	the metabolism of one or a group of	without electrolytes must not be
metabolism	amino acids.	used in patients with inborn
	Inborn errors of amino acid metabolism usually present in infancy and early childhood. However in some rare	 errors of amino acid metabolism. The existence of such a disorder must be immediately brought to the attention of the treating
	cases it can present in adulthood e.g. when patients are exposed to	physician. This is part of the careful evaluation of each patient's medical history before
	increased protein intake or certain medications	treatment is started.
	and infections. The most common amino acid disorders	
	are phenylketonuria, urea cycle	
	disorders, nonketonic hyperglycinaemia,	
	tyrosinaemia and maple syrup disease.	
	Treatment includes severe restriction of	
	natural protein intake, combined with an	
	amino acid supplement which substitutes	
	all necessary amino acids, excluding the	
	one(s) affected by the metabolic defect.	
	Nutriflex Omega special without	
	electrolytes is a standard product with an	
	amino acid composition of a natural high	
	quality protein. The different inborn	
	errors of amino acid metabolism require	
	specific, different adaptions of the amino	
	acid composition that a standard product	
	cannot provide.	
Fat overload syndrome	'Fat Overload Syndrome' results when the lipid	• Recommended doses of Nutriflex Omega special
	infusion rate exceeds the	without electrolytes should not
	ability of the body to	be exceeded.
	utilize the lipids. The	Blood lipids have to be
	clinical symptoms of 'Fat	controlled and dosage adjusted
	Overload Syndrome' are	as necessary.
	complex. They include elevation of blood lipid	Overnutrition must be avoided.
	levels, fever, enlarged	
	ieveis, ievei, einargeu	

Important identif	ied risks	
Risk	What is known	Preventability
	liver with or without	
	jaundice, enlarged	
	spleen, decreased number	
	of red and white blood	
	cells, decreased platelets	
	in blood, blood clotting	
	disorders, break-up of red	
	blood cells, abnormal	
	liver function tests and	
	coma.	
	Fat overload syndrome	
	has been described for	
	dosages of parenteral	
	lipids higher than	
	recommended in the	
	product information.	
	Patients with impaired	
	lipid utilization, e.g.	
	diabetes, impaired	
	function of the kidneys,	
	liver or the thyroid gland,	
	inflammation of the	
	pancreas or sepsis are at	
	risk for fat overload	
	syndrome.	
Disturbance	Blood clotting	Nutriflex Omega special
of blood	(coagulation) may be	without electrolytes must not be
coagulation	impaired in patients in	used in patients with severely
(bleeding)/or	poor overall condition	impaired blood clotting
tendency to	putting them into an	function.
form blood	increased risk of	• Coagulation status should be
clots	bleeding. Also patients	continuously monitored
(thrombosis)	suffering from genetic	especially, in patients treated
	disorders like	concomitantly with
	haemophilia or patients	anticoagulants or antiplatelet
	treated with drugs	drugs.
	decreasing blood	
	coagulation	
	(anticoagulants) or	
	antiplatelet agents (e.g.	
	aspirin) are exposed to a	
	higher risk of bleeding.	
	Blood clotting should be	

Important identi	fied risks	
Risk	What is known	Preventability
	under control before	
	parenteral nutrition via	
	intravenous catheter	
	should be started.	
	On the other hand	
	patients with in a poor	
	state of health as well as	
	bedridden patients are	
	also often exposed to a	
	higher risk of	
	development of blood	
	clots in the blood stream,	
	which theoretically may	
	be increased after	
	infusion of soybean oil	
	emulsion.	
High blood sugar	High blood sugar may	• The rate of infusion should be
(Hyperglycaemia)	occur as a result of a high	reduced or insulin should be
	rate of administration or	administered in case that
	impaired utilisation of	hyperglycaemia occurs.
	glucose. Glucose is	• If the patient is receiving other
	excreted in urine when	glucose solutions concurrently,
	the blood glucose level	this amount has to be taken into
	reaches a critic level	account.
	(renal threshold).	Blood levels of glucose should
	Excretion of glucose is	be monitored.
	accompanied by	• An interruption of
	increased urination. If	administration of Nutriflex
	untreated, this can lead to	Omega special without
	excessive loss of fluid	electrolytes may be indicated if
	which may be life-	the blood glucose concentration
	threatening.	reaches a critical level during
	Increased blood sugar	administration and cannot be
	can be transformed into	controlled by appropriate
	triglycerides which may	amounts of insulin.
	cumulate in the liver	
	leading to the	
	development of fatty	
	liver.	
	Nutriflex Omega special	
	without electrolytes	
	contains glucose and its	

Important identit	ried risks	
Risk	What is known	Preventability
	administration can lead to hyperglycaemia.	
Impaired bile flow (Cholestasis)	Cholestasis is a condition in which bile cannot be sufficiently drained into the intestine. As a result, bile stagnates in the gallbladder and eventually also within the liver, impairing liver function (intrahepatic cholestasis). Infusion of fat emulsions may further enhance cholestasis.	Nutriflex Omega special without electrolytes must not be used in case of intrahepatic cholestasis. Liver function must be monitored during parenteral nutrition.
Fluid deficit or water excess in the body/ disturbances of the body salt composition	Administration of intravenous solutions may cause disturbances of the body salt and fluid balance. The risk of such undesirable effects is enhanced in case of infusion of too large volumes (hyperhydration) or a too rapid infusion as well as in severely ill and pediatric patients or patients with impaired cardiac or renal function who all have limited ability to maintain the fluid balance. In patients with pre-existing disturbances of fluid and salt balance, the disorder may be aggravated by infusion of intravenous solutions. Severer salt imbalances can lead to shifts in the body fluids with the accumulation of fluid in certain tissues like the lungs (lung	 Disturbances of the fluid and salt balance must be corrected before the start of infusion. The infusion rate should be appropriately dosed. Regular controls of the blood composition are necessary. Sufficient amounts of electrolytes must be administered together with Nutriflex Omega special without electrolytes according to the patient's requirements.

Important identified i	risks	
Risk	What is known	Preventability
	oedema) or the brain.	
	Untreated these	
	conditions can result in	
	serious complications	
	and permanent damage.	
	A special kind of a body	
	salt imbalance (acidosis)	
	is when the body	
	produces too much acid	
	(e.g. decompensated	
	diabetes or glucose	
	utilization with lack of	
	oxygen in the tissues), or	
	when the elimination of	
	acids from the body is	
	impaired (e.g. renal	
	insufficiency or	
	inadequate ventilation).	
	Nutriflex Omega special	
	without electrolytes does	
	not contain electrolytes.	
	Therefore sufficient	
	amounts of electrolytes	
	must be administered	
	together with this product	
	according to the patient's	
	requirements. A	
	sufficient potassium	
	substitution has to be	
	ensured.	
Refeeding	Refeeding syndrome is a	• In starved or severely mal-
syndrome	disturbance that occurs as	nourished patients the nutrition
	a result of reinstitution of	must be reinstituted slowly and
	nutrition to patients who	gradually.
	are starved or severely	An adequate supplementation
	malnourished. Refeeding	of salts according to deviations
	or repletion of such	from normal values is
	patients may lead to	necessary.
	deficiency of some	Regular controls of the blood
	essential salts in the	composition is necessary.
	body, i.e. potassium,	r

Important identi	fied risks	
Risk	What is known	Preventability
	phosphorus and	
	magnesium.	

Missing information	
	What is known
Pregnancy and lactation	There are no or limited amount of data from the use of Nutriflex Omega special without electrolytes in pregnant women. Parenteral nutrition may become necessary during pregnancy. Nutriflex Omega special without electrolytes should only be given to pregnant women after careful consideration. Components/metabolites of Nutriflex Omega special without electrolytes are excreted in human milk, but at therapeutic doses no effects on the breastfed newborns/infants are anticipated. Nevertheless, breast-feeding is not recommended for mothers on parenteral nutrition.
Patients with diabetes mellitus and renal failure	There is only limited experience of the use of Nutriflex Lipid special without electrolytes in patients with diabetes mellitus or renal failure. Like all large-volume infusion solutions, Nutriflex Omega special without electrolytes should be administered with caution to patients with impaired renal function. The doses should be adjusted individually in patients with renal insufficiency. Patients with diabetes mellitus are particularly prone to hyperglycemia. Therefore the dosage should be adopted to the patients' individual needs and glucose tolerance. A slow and stepwise increase of the infusion rate to the desired infusion rate avoids possible complications. The blood glucose level should be monitored. If there is hyperglycaemia the rate of infusion should be reduced or insulin should be administered. An interruption of administration of the emulsion may be indicated if the blood glucose concentration rises to above 14 mmol/l (250 mg/dl) during administration. If the patient is receiving other intravenous glucose solutions concurrently, the amount of additionally administered glucose has to be taken into account.
Paediatric patients	Due to its composition (amino acid composition, the relation of the macronutrients) Nutriflex Omega special without electrolytes is contraindicated in newborn infants, infants and toddlers under 2 years of age.

Up to now there is no clinical experience with the use of Nutriflex Omega special without electrolytes in children > 2
years.

VI.2.5. Summary of additional risk minimisation measures by safety concern

Not applicable. No additional risk minimisation measures are planned.

VI.2.6. Planned post authorisation development plan

Not applicable.

VI.2.7. Summary of changes to the Risk Management Plan over time

Not applicable, as this is the first EU-RMP for Nutriflex Omega special without electrolytes.